Terms: = Prostate cancer AND BCR, FLJ16453, 613, ENSG00000186716, BCR1, D22S662, D22S11, CML, P11274, PHL, ALL
1798 results:
1. Comparing symptom clusters in cancer survivors by cancer diagnosis: A latent class profile analysis.
Lee LJ; Han CJ; Saligan L; Wallen GR
Support Care Cancer; 2024 Apr; 32(5):308. PubMed ID: 38662054
[TBL] [Abstract] [Full Text] [Related]
2. Limited prognostic role of routine serum markers (AP, CEA, LDH and NSE) in oligorecurrent prostate cancer patients undergoing PSMA-radioguided surgery.
Mehring G; Steinbach C; Pose R; Knipper S; Koehler D; Werner S; Riethdorf S; von Amsberg G; Ambrosini F; Maurer T
World J Urol; 2024 Apr; 42(1):256. PubMed ID: 38656636
[TBL] [Abstract] [Full Text] [Related]
3. [Bioinformatics-based analysis of the effect of general Transcription Factor IIH on prognosis of prostate cancer].
Li JC; Zhu XJ; Ye JH; Tan ZH; Cai SH; Deng YL; Chen J; Tian WC; Luo DH; Zhong WD
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(16):1410-1417. PubMed ID: 38644292
[No Abstract] [Full Text] [Related]
4. An early-onset specific polygenic risk score optimizes age-based risk estimate and stratification of prostate cancer: population-based cohort study.
Cheng Y; Wu L; Xin J; Ben S; Chen S; Li H; Zhao L; Wang M; Cheng G; Du M
J Transl Med; 2024 Apr; 22(1):366. PubMed ID: 38632662
[TBL] [Abstract] [Full Text] [Related]
5. Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients.
Einstein DJ; Aragon-Ching JB; Karzai F; Madan RA
Curr Opin Oncol; 2024 May; 36(3):164-168. PubMed ID: 38573205
[TBL] [Abstract] [Full Text] [Related]
6. Development of risk-score model in patients with negative surgical margin after robot-assisted radical prostatectomy.
Yamada Y; Fujii Y; Kakutani S; Kimura N; Sugimoto K; Hakozaki Y; Sugihara T; Takeshima Y; Kawai T; Nakamura M; Kamei J; Taguchi S; Akiyama Y; Sato Y; Yamada D; Urabe F; Miyazaki H; Enomoto Y; Fukuhara H; Nakagawa T; Fujimura T; Kume H
Sci Rep; 2024 Mar; 14(1):7607. PubMed ID: 38556562
[TBL] [Abstract] [Full Text] [Related]
7. Contemporary risk of biochemical recurrence after radical prostatectomy in the active surveillance era.
Das S; Luu M; Terris M; Klaassen Z; Kane CJ; Amling C; Cooperberg M; Rivera LG; Aronson W; Freedland SJ; Daskivich TJ
Urol Oncol; 2024 Jun; 42(6):175.e1-175.e8. PubMed ID: 38490923
[TBL] [Abstract] [Full Text] [Related]
8. Nadir prostate-specific antigen after salvage cryotherapy as a potential prognostic factor for oncologic outcomes.
Carbonell E; Mercader C; Sureda J; Gutiérrez A; Muñoz J; Gallardo E; Feltes N; Mases J; Valduvieco I; Vilaseca A; Franco A; Alcaraz A; Musquera M; Ribal MJ
World J Urol; 2024 Mar; 42(1):133. PubMed ID: 38478102
[TBL] [Abstract] [Full Text] [Related]
9. Significance of the cribriform morphology area ratio for biochemical recurrence in Gleason score 4 + 4 prostate cancer patients following robot-assisted radical prostatectomy.
Shimodaira K; Inoue R; Hashimoto T; Satake N; Shishido T; Namiki K; Harada K; Nagao T; Ohno Y
Cancer Med; 2024 Mar; 13(5):e7086. PubMed ID: 38477506
[TBL] [Abstract] [Full Text] [Related]
10. Cumulative cancer locations on prostate biopsy and active surveillance outcomes in the MRI era.
Fletcher SA; Mamawala MM; Holler AE; Bhanji Y; Macura KJ; de la Calle CM; Pavlovich CP
Prostate; 2024 Jun; 84(8):723-730. PubMed ID: 38476030
[TBL] [Abstract] [Full Text] [Related]
11. European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy.
Scharl S; Zamboglou C; Strouthos I; Farolfi A; Serani F; Koerber SA; Debus J; Peeken JC; Vogel MME; Kroeze SGC; Guckenberger M; Krafcsik M; Hruby G; Emmett L; Schmidt-Hegemann NS; Trapp C; Spohn SKB; Henkenberens C; Mayer B; Shelan M; Aebersold DM; Thamm R; Wiegel T
Radiother Oncol; 2024 May; 194():110215. PubMed ID: 38458259
[TBL] [Abstract] [Full Text] [Related]
12. Do Hispanic Puerto Rican men have worse outcomes after radical prostatectomy? Results from SEARCH.
Guerrios-Rivera L; Janes JL; De Hoedt AM; Klaassen Z; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ; Fowke JH; Freedland SJ
Cancer Med; 2024 Feb; 13(4):e7012. PubMed ID: 38457188
[TBL] [Abstract] [Full Text] [Related]
13. Implementation of PSMA PET/CT and alignment of ordering to SNMMI appropriate use criteria in a large network system.
Bennett R; Li EV; Ho AY; Aguiar JA; Neill C; Rowe SP; Patel HD; Savas H; Ross AE
Prostate; 2024 Jun; 84(8):717-722. PubMed ID: 38450787
[TBL] [Abstract] [Full Text] [Related]
14. The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer.
Teppala S; Scuffham PA; Tuffaha H
Int J Technol Assess Health Care; 2024 Mar; 40(1):e14. PubMed ID: 38439629
[TBL] [Abstract] [Full Text] [Related]
15. Salvage Therapy for prostate cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical prostatectomy.
Morgan TM; Boorjian SA; Buyyounouski MK; Chapin BF; Chen DYT; Cheng HH; Chou R; Jacene HA; Kamran SC; Kim SK; Kirkby E; Luckenbaugh AN; Nathanson BJ; Nyame YA; Posadas EM; Tran PT; Chen RC
J Urol; 2024 Apr; 211(4):509-517. PubMed ID: 38421253
[TBL] [Abstract] [Full Text] [Related]
16. Salvage Therapy for prostate cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.
Morgan TM; Boorjian SA; Buyyounouski MK; Chapin BF; Chen DYT; Cheng HH; Chou R; Jacene HA; Kamran SC; Kim SK; Kirkby E; Luckenbaugh AN; Nathanson BJ; Nyame YA; Posadas EM; Tran PT; Chen RC
J Urol; 2024 Apr; 211(4):526-532. PubMed ID: 38421252
[TBL] [Abstract] [Full Text] [Related]
17. Salvage Therapy for prostate cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical prostatectomy.
Morgan TM; Boorjian SA; Buyyounouski MK; Chapin BF; Chen DYT; Cheng HH; Chou R; Jacene HA; Kamran SC; Kim SK; Kirkby E; Luckenbaugh AN; Nathanson BJ; Nyame YA; Posadas EM; Tran PT; Chen RC
J Urol; 2024 Apr; 211(4):518-525. PubMed ID: 38421243
[TBL] [Abstract] [Full Text] [Related]
18. DARDN: A Deep-Learning Approach for CTCF Binding Sequence Classification and Oncogenic Regulatory Feature Discovery.
Cho HJ; Wang Z; Cong Y; Bekiranov S; Zhang A; Zang C
Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397134
[TBL] [Abstract] [Full Text] [Related]
19. Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: A benchmarking study using ten machine learning methods and twelve patient cohorts.
Yin W; Chen G; Li Y; Li R; Jia Z; Zhong C; Wang S; Mao X; Cai Z; Deng J; Zhong W; Pan B; Lu J
Cancer Lett; 2024 Apr; 588():216739. PubMed ID: 38395379
[TBL] [Abstract] [Full Text] [Related]
20. [
Rosar F; Burgard C; Larsen E; Khreish F; Marlowe RJ; Schaefer-Schuler A; Maus S; Petto S; Bartholomä M; Ezziddin S
Cancer Imaging; 2024 Feb; 24(1):27. PubMed ID: 38389092
[TBL] [Abstract] [Full Text] [Related]
[Next]
